Renzo Zaldivar, MD
Ophthalmic Plastic and Reconstructive Surgery · Cary, NCNPI 1548234313
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Amgen at 58.8% of the total. Reporting peaked in 2022 at $3,003 and has fallen 85.7% since, to $431 in 2025.
Across 60 payments — averaging $80.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Biotissue Holdings Inc.$1K
- Alcon$279
- Genentech USA, Inc.$158
- Glaukos Corporation$132
- Shire North American Group Inc$115
- plus $103 from 2 others
What the payments were for
- Speaking & faculty fees$1,74036%
- Travel & lodging$58712%
- Food & beverage$2,49752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 41 | $2,837 |
| Biotissue Holdings Inc. | 11 | $1,201 |
| Alcon | 2 | $279 |
| Genentech USA, Inc. | 2 | $158 |
| Glaukos Corporation | 1 | $132 |
| Shire North American Group Inc | 1 | $115 |
| Ocular Therapeutix, Inc. | 1 | $89 |
| Conmed Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$2,227
- Prokera$348
- AmnioGraft$348
- NGENUITY$149
- Erivedge$135
- AcrySof IQ VIVITY IOL$130
- XIIDRA$115
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 402 | $4,689 |
| ErythromycinErythromycin Base | 45 | $477 |
| Fluticasone Propionate | 15 | $159 |
| Lorazepam | 76 | $53 |
| Diazepam | 60 | $47 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Cary
- Molly FullerBermuda Run$104K
- Christopher DermarkarianDurham$2K
- Christina ChoeAsheville$2K
- Jeffrey GoldsteinAsheville$875
- Ryan NolanDurham$701
- Benjamin MeyerDurham$400
- Samantha PrabakaranRaleigh$280
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.